[1]熊效墨,马爱霞.从需求方和供给方角度测算成本—效果阈值研究[J].卫生经济研究,2019,(05):39-42.
　XIONG Xiao-mo,MA Ai-xia.Cost-effectiveness Threshold Research from the Perspective of Demand Side and Supply Side[J].Journal Press of Health Economics Research,2019,(05):39-42.
点击复制

从需求方和供给方角度测算成本—效果阈值研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年05期
页码:
39-42
栏目:
成本与费用
出版日期:
2019-04-26

文章信息/Info

Title:
Cost-effectiveness Threshold Research from the Perspective of Demand Side and Supply Side
作者:
熊效墨1; 马爱霞1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
XIONG Xiao-mo; MA Ai-xia
International Pharmaceutical Business School，China Pharmaceutical University，Nanjing Jiangsu 211198，China
关键词:
成本—效果分析; 成本—效果阈值; 机会成本; 意愿支付
Keywords:
cost-effectiveness analysis;  cost-effect threshold;  opportunity cost;  willingness to pay
分类号:
R19
文献标志码:
A
摘要:
随着卫生资源耗费的增加，基于价值的医疗卫生干预措施越来越受到重视，成本—效果阈值作为判断不同医疗干预措施经济性的工具，其重要性日益显现。本文基于实证，介绍了从需求方和供给方两种角度出发的成本—效果阈值测算方法，探索在不同背景、不同环境使用不同成本—效果阈值测算方法的可能性。
Abstract:
As the consumption of health resources increases， value-based health interventions are increasingly valued， and cost-effectiveness thresholds are increasingly important as tools for judging the economics of different medical interventions. Based on the empirical evidence， this paper introduced the cost-effect threshold measurement method from the perspective of demand side and supply side， and explored the possibility of using different cost-effect threshold measurement methods in different backgrounds and environments.

参考文献/References:

[1] 宗欣, 孙利华. 从多国视角看成本效果阈值的应用现状[J]. 中国药事, 2011(8):768-771.
[2] SANTOS A S, GUERRA-JUNIOR A A, GODMAN B, et al. Cost-effectiveness thresholds: methods for setting and examples from around the world[J]. Expert Rev Pharmacoecon Outcomes Res, 2018,18(3):277-288.
[3] VALLEJO-TORRES L, GARCIA-LORENZO B, CASTILLA I, et al. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?[J]. Value Health, 2016,19(5):558-566.
[4] BALA M V, MAUSKOPF J A, WOOD L L. Willingness to pay as a measure of health benefits[J]. Pharmacoeconomics, 1999,15(1):9-18.
[5] MASON H, JONES-LEE M, DONALDSON C. Modelling the monetary value of a QALY: a new approach based on UK data[J]. Health Economics, 2009,18(8):933-950.
[6] APPLEBY J, DEVLIN N, PARKIN D, et al. Searching for cost effectiveness thresholds in the NHS[J]. Health Policy, 2009,91(3):239-245.
[7] SLOAN F A. Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies[M]. Cambridge University Press, 1996.
[8] ROBINSON L A, HAMMITT J K, CHANG A Y, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds[J]. Health Policy Plan, 2017,32(1):141-145.
[9] BAKER R, CHILTON S, DONALDSON C, et al. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE[J]. Health Econ Policy Law, 2011,6(4):435-447.
[10]周挺, 李洪超, 马爱霞, 等. 药物经济学评价中生命终末期患者意愿支付阈值探讨[J]. 卫生经济研究, 2018(3):55-57.
[11] DUBOIS R W. Cost-effectiveness thresholds in the USA: are they coming? Are they already here?[J]. J Comp Eff Res, 2016,5(1):9-11.

更新日期/Last Update: 2019-04-26